Improving on R-ICE in relapsed DLBCL

Abstract

In this issue of Blood, Sauter et al report the results of a multicenter phase 1 study of rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in combination with ibrutinib in relapsed/refractory diffuse large B-cell lymphoma. 1 This combination was well tolerated and resulted in high response rates.Therapies to improve survival among patients with relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are greatly needed, notwithstanding the newly approved chimeric antigen receptor T cell for second relapse of DLBCL. 2